MGEN stock is running in early trading on January 24, 2020, after the company announced that it will be presenting clinical trial data next week.

miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that it will present new efficacy and safety data from its Phase 1 trial of cobomarsen in adult T-cell leukemia/lymphoma (ATLL) at the 12th Annual T-Cell Lymphoma Forum, which is being held in La Jolla, CA, from January 30th to February 1st.

Presentation Details:

Poster title: Phase I Trial of Cobomarsen, a miR-155 Inhibitor, in Patients with Aggressive HTLV-1 Associated ATLL: Disease Stabilization and Biomarker Analysis
Presenter: Francine Foss, MD; Yale University School of Medicine
Date: Friday, January 31, 2020
Time: 6:10PM-8:00PM PT
Location: Hilton La Jolla Torrey Pines

Oral presentation title: Clinical Development of microRNA Inhibitors
Presenter: Diana Escolar, MD, FAAN, miRagen Chief Medical Officer
Date: Saturday, February 1, 2020
Time: 11:50AM-12:10 PM PT
Location: Hilton La Jolla Torrey Pines

In addition, miRagen will also participate in the 4th World Congress of Cutaneous Lymphomas, which is taking place from February 12th to 14th in Barcelona, Spain. During the conference, Dr. Foss will provide an encore presentation of the new ATLL data in the poster titled, “Phase I Trial of Cobomarsen, a miR-155 Inhibitor, in Patients with Aggressive HTLV-1 Associated ATLL: Disease Stabilization and Biomarker Analysis”.

finviz dynamic chart for  mgen

To get these stocks much faster (real-time) with alerts, check out the tool we use here. There’s nothing like it on the market.

Miragen Therapeutics News From Google